Hyatt Regency Orlando
9801 International Drive
Orlando, FL 32819
Hotel Phone: (407) 284-1234

Meeting Room:
Florida Ballroom (C Level)

Time:
6:15 AM – 7:45 AM

Breakfast buffet will be provided to registered attendees.

An older woman receives intraperitoneal (IP) chemotherapy for Stage IIIC ovarian cancer (OC)
CASE 1: A 73-year-old retired homemaker and grandmother with optimally debulked Stage IIIC OC experienced postoperative complications, including small bowel obstruction and pulmonary embolism. She then received 2 cycles of IV carboplatin/paclitaxel, tolerated it well and was transitioned to IV/IP chemotherapy for an additional 4 cycles. Side effects were primarily gastrointestinal and included nausea without emesis, bloating, gas and constipation. She also experienced oral candidiasis, fatigue (Hb = 9 g/dL) and mild shortness of breath on exertion. She received 1 liter of IV hydration fluid for 2 days after each cycle of IP chemotherapy. Postchemotherapy CT shows no evidence of disease. The patient enjoys crocheting and knitting and has become more proactive and confident throughout her treatment course. (Ms Anastasia)

DISCUSSION TOPICS:

• Histopathologic subtypes of OC and implications for clinical decision-making
• Multidisciplinary consultation in the primary management of epithelial OC
• Clinical and biologic factors affecting the selection of initial therapy for patients with Stage III disease
• Available clinical data with, tolerability of and current indications for IP chemotherapy
• Supportive management considerations for patients receiving IP chemotherapy
• Current role, if any, of bevacizumab as a component of primary and/or maintenance therapy in newly diagnosed OC

A woman with high-grade serous OC seeks a second opinion after being referred for hospice care
CASE 2: A 71-year-old woman who works as an office assistant in a local parish was initially diagnosed with Stage IIIC, high-grade serous OC in 2011, underwent debulking surgery and received multiple lines of systemic therapy during the next 3 years. In December 2014 PET-CT revealed disease progression in the liver, and the patient was offered a choice of liver biopsy and treatment or hospice care. After a second-opinion consultation, a genetic evaluation was conducted, which revealed a BRCA1 germline mutation. The patient began receiving olaparib in April 2015. Her husband of 34 years, a grocery store manager who is 15 to 20 years her junior, is very supportive and accompanies her on office visits. (Ms Gonzalez)

DISCUSSION TOPICS:

• Guideline recommendations regarding BRCA analysis for patients with OC
• Similarities and differences between commercially available BRCA testing platforms and the information they provide
• Implications of a positive BRCA mutation test result for treatment decision-making
• Therapeutic options for platinum-sensitive and platinum-resistant disease
• Available efficacy and safety data guiding the use of bevacizumab alone or in combination with chemotherapy in the setting of platinum-sensitive or platinum-resistant recurrent OC
• Recent FDA approval and current incorporation of olaparib into the treatment algorithm for patients with recurrent OC
• Effect of BRCA mutation status on the efficacy of olaparib

A younger woman with dependent children develops brain metastases
CASE 3: A 46-year-old woman with 3 daughters aged 14, 17 and 20 underwent optimal debulking surgery for Stage IIIC OC with a BRCA1 germline mutation. She received postoperative carboplatin and dose-dense paclitaxel for 4 cycles. Six months later she presented with headaches, and imaging revealed cerebral and cerebellar lesions. She received whole brain radiation therapy and temozolomide, with complete remission of the brain lesions. Two months later a routine CT scan showed retroperitoneal and hilar adenopathy, for which she received carboplatin/liposomal doxorubicin for 6 cycles. She was referred for a clinical trial of niraparib versus placebo but did not qualify, and she began olaparib. The patient travels with her youngest daughter’s volleyball team, enjoys painting and playing the piano and attends support groups twice a month. (Ms Anastasia)

DISCUSSION TOPICS:

• Selection and sequencing of evidence-based treatment options; current availability of pegylated liposomal doxorubicin
• Available data with olaparib as maintenance therapy for patients with recurrent OC
• Prevention and/or management of the gastrointestinal toxicities (eg, nausea, diarrhea) associated with olaparib
• Incidence of anemia in patients receiving olaparib
• Counseling family members of patients with an identified BRCA mutation regarding their risk of developing the disease and seeking genetic testing

A woman receives IP chemotherapy and is enrolled on a diet and exercise research protocol
CASE 4: A 58-year-old scientific writer received postoperative cisplatin/paclitaxel for Stage IIIC, poorly differentiated serous OC with significant side effects after the first cycle, including nausea, abdominal pain and tinnitus. Her treatment was switched to carboplatin/paclitaxel, which she tolerated well and completed in March 2014. She was enrolled on the GOG-225 LIvES study evaluating diet and exercise as an intervention for patients with OC and was randomly assigned to the intensive activity arm, which she approached with great enthusiasm. In December 2014 she experienced disease progression in the abdomen. The patient is highly independent, and it is important to her that she feel well enough to continue working. (Ms Gonzalez)

DISCUSSION TOPICS:

• Rationale for IP chemotherapy after disease recurrence
• Diet and exercise as an intervention for patients with OC
• Communicating expected risks and side effects of various chemotherapeutic and biologic approaches, and developing effective patient care plans
• Clinical trial participation as an important clinical treatment option

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer (OC).

Learning Objectives

• Apply existing and emerging research data to the therapeutic and supportive care of patients with OC.
• Use case-based learning to gain familiarity with new therapeutic strategies for OC in order to facilitate improved counseling for patients.
• Develop an evidence-based algorithm for the prevention and amelioration of side effects associated with chemotherapeutic and biologic agents used in the management of OC.
• Appreciate the recent FDA approval of olaparib for patients with highly refractory advanced OC, and safely integrate this therapeutic option into clinical practice.
• Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with OC to optimize clinical and quality-of-life outcomes.
• Recall ongoing trials of investigational approaches and agents in OC, and refer patients and obtain consent for study participation.

Accreditation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

To obtain a certificate of completion and receive credit for this event, attendees must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity. Your certificate will be mailed to you within 4 to 6 weeks. International clinicians, please note: In order for a certificate of completion to be issued, you must provide a valid email address.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Gonzalez has no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Ms Anastasia — Speakers Bureau: Eisai Inc, Genentech BioOncology. Dr Armstrong — Advisory Committee: Eisai Inc; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech BioOncology, Incyte Corporation, MedImmune Inc, VentiRx Pharmaceuticals Inc; Other Remunerated Activities: Abbott Laboratories, Sanofi. Dr Monk — Consulting Agreements: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Cerulean Pharma Inc, Genentech BioOncology, GlaxoSmithKline, Gradalis Inc, Merck, Roche Laboratories Inc, TESARO Inc, Verastem Inc; Contracted Research: Amgen Inc, Array BioPharma Inc, Genentech BioOncology, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Novartis Pharmaceuticals Corporation, TESARO Inc; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

Research To Practice staff and external reviewers — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Hyatt Regency Orlando
9801 International Drive
Orlando, FL 32819
Hotel Phone: (407) 284-1234

Meeting Room:
Florida Ballroom (C Level)

Directions:
The Hyatt Regency Orlando hotel is conveniently located within walking distance (5 to 10 minutes) of the Orange County Convention Center and is the host hotel for the ONS 40^th Annual Congress.

» View directions

Thank you for your interest in our CNE program. At this time preregistration is closed for this event as we have reached seating capacity. Onsite standby registration will be open starting at 5:15 AM on Saturday, April 25. If you are interested in standby registration, please visit our onsite registration desk located outside the Florida Ballroom (C Level) at the Hyatt Regency Orlando, Orlando, Florida (9801 International Drive).

If seats become available for the program, we will accept standby registrations on a first come, first served basis prioritized for healthcare professionals directly involved in the care of patients.

Please note, standby registration DOES NOT GUARANTEE participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.